IDIOPATHIC MEMBRANOUS NEPHROPATHY TREATMENT MARKET ANALYSIS
Global Idiopathic Membranous Neuropathy Treatment Market Restraints
According to the journal of American Society of Nephrology, 2012, some side effects have been reported in association with the drugs prescribed for idiopathic membranous nephropathy. For instance, osteoporosis (decrease in the muscle activity of the patients), hyperglycemia, secondary diabetes, impairment of fertility and teratogenic effects during pregnancy are some of the side-effects. Rituximab, has not been approved by U.S. FDA till date for nephropathy. However, it has been approved for treatment of other diseases like rheumatoid arthritis, lupus, vasculitis, and dermatomyositis. These factors are expected to limit growth of the global idiopathic membranous nephropathy treatment market over the forecast period.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :